Lundbeck hikes annual forecasts as migraine drug powers earnings beat

Nov 10 (Reuters) – Danish drugmaker Lundbeck raised its full-year sales and profit forecasts on Tuesday after third-quarter earnings beat expectations, citing strong demand for its migraine treatment Vyepti in the United States.

Shares were up around 5% by 1116 GMT, hitting a new record high.

• Quarterly adjusted core earnings (EBITDA) came in at 2.26 billion Danish crowns ($339 million), above the company-compiled consensus of 1.95 billion

• The drugmaker now expects annual revenue growth of 11% to 12% at constant exchange rates compared with 7% to 9% seen previously

• Lundbeck expects annual adjusted EBITDA growth in 2026 of 15% to 19%, up from 8% to 14%

• Vyepti sales rose 44% at constant currencies to 1.67 billion crowns

• Still, the company lowered its 2026 profit margin forecast to 86%-87% from around 87%, citing higher production costs

• Lundbeck expects Q4 revenue growth to moderate, due to generic competition for antidepressant Trintellix from December and intensifying competition for antipsychotic drug Rexulti

• It also sees research and development investments of about 5.6 to 5.7 billion crowns

($1 = 6.6576 Danish crowns)

(Reporting by Vera Dvorakova and Jesus Calero in Gdansk; Editing by)